Emerging Basal Insulins for Diabetes

Slides:



Advertisements
Similar presentations
In the name of GOD In the name of GOD.
Advertisements

Diabetes Update Matt Bouchonville, MD Endocrinology Division University of New Mexico ACP New Mexico Chapter Scientific Meeting November 7, 2014
New Insulin Glargine 300 Units/mL Versus Glargine 100 Units/mL in People With Type 2 Diabetes Using Basal and Mealtime Insulin: Glucose Control and Hypoglycemia.
Insulin therapy.
New Insulin Formulations
Basal Bolus: The Strategy for Managing All Diabetes Fall, 2003 Paul Davidson, MD, FACE Atlanta Diabetes Associates Atlanta, Georgia.
New Insulin Formulations
New Insulin Formulations Guillermo Umpierrez, MD, FACP, FACE Professor of Medicine Emory University School of Medicine Part 1.
Introduction Subcutaneous insulin absorption is not reproducible and insulin entry directly into the circulation is not linked to glucose sensing Basal.
What's New in Basal Insulin for Diabetes
Mastery of Medicine in Diabetes Management Video Roundtable
Insulin Degludec Drugbank ID :DB09564
Short-, Intermediate-, Long-Acting Insulins
Engaging the INSULIN-TREATED T2DM Patient: the Importance of Real-World Data.
Applying Data to Practice
Special Consideration in Insulin Therapy
Faster-Acting Insulins
Program Goals. Inhaled Insulin: Overcoming Past Obstacles With Advances in Understanding.
Using the AGP to Standardize Glucose Reporting
T1DM: Insulin Initiation
New Patient-Friendly Options for Managing Insulin Dosing
The Next Generation of Basal Insulins
Modern Strategies for Basal Insulin Use in T2D
Patient Case Discussions in T2D: What Intensification Plan Is Best?
Insulin Innovation.
Introduction Antiplatelet Agents ADP Receptor Antagonists.
Differentiating Among Incretin Agents for Type 2 Diabetes: Weighing the Evidence.
Insulin Intensification Strategies in Later-Stage Type 2 Diabetes Mellitus.
How Early Should Basal Insulin Be Used in T2D Management?
Novel Concentrated Insulins: What Benefits and for Which Patients?
Updates Abound.
Examining CV Effects of Basal Insulin Therapy
What Do Primary Care Physicians Need to Know About Insulin/GLP-1 RA Fixed-Ratio Combinations?
Innovative Insulin Combinations: A New strategy for the Person With T2DM.
Program Goals. What Will the Emerging Basal Insulin Products Mean for My Diabetes Practice?
Insights into Insulin Treatment Challenges: Real-World Evidence and Clinical Trial Data.
GLP-1 Receptor Agonists: How Early Is Appropriate?
Talking to Patients About Diabetes Management
Novel Insulin Combinations: What Does the Primary Care Physician Need to Know?
Integrated Diabetes Care: How Can We Make the Best Use of New Technology?
Novel Basal Insulin Formulations in the Modern Era of T2D Management
Insulin Use in Primary Care: Practice Challenges
Insulin Innovation.
Injectable Options as Add-Ons to Basal Insulin: Targeting PPG in Type 2 Diabetes Patients.
New Horizons in Adjunctive Type 1 Diabetes Management With SGLT Inhibitors.
Simplifying Insulin Delivery for Better Patient Outcomes in T2D
Predictive Low Glucose Suspend (PLGS)
Novel Approaches to T1D Management
The Cardiologist's Mindset in the Management of Diabetes and Coronary Artery Disease: Today and Tomorrow.
T2DM Management.
Better Diabetes Control With Novel Basal Insulins
Novel Insulin/GLP-1 Combinations: Of Interest to the Primary Care Physician?
Program. Basal Insulin in the Modern Era The CDE's Role in Improving Utilization and Outcomes.
Younger Patients With Type 1 Diabetes: Can We Optimize Their Insulin Therapy?
Panelists. Cardiovascular Risk Modulation in Diabetes: Emerging Pathways and Insights.
Frequency of potential risk of hypoglycemia for each estimate method, defined as a percentage difference between the estimate and final basal rate. Frequency.
Insulin in Diabetes Management: Effective Patient Selection Is Key
COMBINATIONS AND COFORMULATIONS: THE FUTURE OF INSULIN THERAPY?
Liraglutide Shows CV Benefit: Clinical Perspectives on the LEADER Trial
Figure 3 Pharmacodynamic action profiles of long-acting insulins
Hypoglycemia Is BAD.
Improving Effective Basal Insulin Use in Clinical Practice
Are All Novel Insulins Proven to Be Equally Safe?
Emerging Combination Injectable Therapy A New Era in Diabetes Care
Type 1 Diabetes: Expanding Options for Adjunctive Oral Therapy With SGLT Inhibitors.
INSULINS Dr.R.Sajjad december INSULINS Dr.R.Sajjad december 2018.
Fixed-Ratio Combination Therapy in T2DM
Emerging Basal Insulins for Diabetes
Fresh perspectives ON BASAL Insulins in diabetes care
The Challenge of Insulin Titration
Presentation transcript:

Emerging Basal Insulins for Diabetes

Program Goals

The Barrier of Hypoglycemia in Diabetes

Hypoglycemia and Cardiovascular Events

Insulin Glargine U-300

Reductions in Nocturnal Hypoglycemia With U-300

PK/PD Profile Glargine U-300

EDITION I-III (Meta-analysis) Nocturnal Hypoglycemia (Rates)

EDITION I-III (Meta-analysis) Body Weight

EDITION I-III (Meta-analysis) Basal Insulin Doses

Insulin Degludec An Ultra-Long-Acting Basal Insulin Analog

Insulin Degludec Pharmacodynamics at Steady State

Insulin Degludec Duration of Action

Insulin Degludec Low Within-Patient Variability

Insulin Degludec vs Insulin Glargine Hypoglycemia Results

Emerging Intensification Strategy

Peglispro (BIL)*

Key Takeaway Points of Next-Generation Basal Insulin Analogs

Abbreviations

Abbreviations (cont)

References

References (cont)

References (cont)

References (cont)

References (cont)

References (cont)